Cargando…
Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis
BACKGROUND: Lafora disease (LD) is a rare fatal autosomal recessive form of progressive myoclonus epilepsy. It affects previously healthy children or adolescents, causing pharmacoresistant epilepsy, myoclonus and severe psychomotor deterioration. This work aims to describe the clinical course of LD...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365996/ https://www.ncbi.nlm.nih.gov/pubmed/34399803 http://dx.doi.org/10.1186/s13023-021-01989-w |
_version_ | 1783738824043528192 |
---|---|
author | Pondrelli, Federica Muccioli, Lorenzo Licchetta, Laura Mostacci, Barbara Zenesini, Corrado Tinuper, Paolo Vignatelli, Luca Bisulli, Francesca |
author_facet | Pondrelli, Federica Muccioli, Lorenzo Licchetta, Laura Mostacci, Barbara Zenesini, Corrado Tinuper, Paolo Vignatelli, Luca Bisulli, Francesca |
author_sort | Pondrelli, Federica |
collection | PubMed |
description | BACKGROUND: Lafora disease (LD) is a rare fatal autosomal recessive form of progressive myoclonus epilepsy. It affects previously healthy children or adolescents, causing pharmacoresistant epilepsy, myoclonus and severe psychomotor deterioration. This work aims to describe the clinical course of LD and identify predictors of outcome by means of a prognostic systematic review with individual participant data meta-analysis. METHODS: A search was conducted on MEDLINE and Embase with no restrictions on publication date. Only studies reporting genetically confirmed LD cases were included. Kaplan–Meier estimate was used to assess probability of death and loss of autonomy. Univariable and multivariable Cox regression models with mixed effects (clustered survival data) were performed to evaluate prognostic factors. RESULTS: Seventy-three papers describing 298 genetically confirmed LD cases were selected. Mean age at disease onset was 13.4 years (SD 3.7), with 9.1% aged ≥ 18 years. Overall survival rates in 272 cases were 93% [95% CI 89–96] at 5 years, 62% [95% CI 54–69] at 10 years and 57% [95% CI 49–65] at 15 years. Median survival time was 11 years. The probability of loss of autonomy in 110 cases was 45% [95% CI 36–55] at 5 years, 75% [95% CI 66–84] at 10 years, and 83% [95% CI 74–90] at 15 years. Median loss of autonomy time was 6 years. Asian origin and age at onset < 18 years emerged as negative prognostic factors, while type of mutated gene and symptoms at onset were not related to survival or disability. CONCLUSIONS: This study documented that half of patients survived at least 11 years. The notion of actual survival rate and prognostic factors is crucial to design studies on the effectiveness of upcoming new disease-modifying therapies. |
format | Online Article Text |
id | pubmed-8365996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83659962021-08-17 Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis Pondrelli, Federica Muccioli, Lorenzo Licchetta, Laura Mostacci, Barbara Zenesini, Corrado Tinuper, Paolo Vignatelli, Luca Bisulli, Francesca Orphanet J Rare Dis Research BACKGROUND: Lafora disease (LD) is a rare fatal autosomal recessive form of progressive myoclonus epilepsy. It affects previously healthy children or adolescents, causing pharmacoresistant epilepsy, myoclonus and severe psychomotor deterioration. This work aims to describe the clinical course of LD and identify predictors of outcome by means of a prognostic systematic review with individual participant data meta-analysis. METHODS: A search was conducted on MEDLINE and Embase with no restrictions on publication date. Only studies reporting genetically confirmed LD cases were included. Kaplan–Meier estimate was used to assess probability of death and loss of autonomy. Univariable and multivariable Cox regression models with mixed effects (clustered survival data) were performed to evaluate prognostic factors. RESULTS: Seventy-three papers describing 298 genetically confirmed LD cases were selected. Mean age at disease onset was 13.4 years (SD 3.7), with 9.1% aged ≥ 18 years. Overall survival rates in 272 cases were 93% [95% CI 89–96] at 5 years, 62% [95% CI 54–69] at 10 years and 57% [95% CI 49–65] at 15 years. Median survival time was 11 years. The probability of loss of autonomy in 110 cases was 45% [95% CI 36–55] at 5 years, 75% [95% CI 66–84] at 10 years, and 83% [95% CI 74–90] at 15 years. Median loss of autonomy time was 6 years. Asian origin and age at onset < 18 years emerged as negative prognostic factors, while type of mutated gene and symptoms at onset were not related to survival or disability. CONCLUSIONS: This study documented that half of patients survived at least 11 years. The notion of actual survival rate and prognostic factors is crucial to design studies on the effectiveness of upcoming new disease-modifying therapies. BioMed Central 2021-08-16 /pmc/articles/PMC8365996/ /pubmed/34399803 http://dx.doi.org/10.1186/s13023-021-01989-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pondrelli, Federica Muccioli, Lorenzo Licchetta, Laura Mostacci, Barbara Zenesini, Corrado Tinuper, Paolo Vignatelli, Luca Bisulli, Francesca Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title | Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title_full | Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title_fullStr | Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title_full_unstemmed | Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title_short | Natural history of Lafora disease: a prognostic systematic review and individual participant data meta-analysis |
title_sort | natural history of lafora disease: a prognostic systematic review and individual participant data meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365996/ https://www.ncbi.nlm.nih.gov/pubmed/34399803 http://dx.doi.org/10.1186/s13023-021-01989-w |
work_keys_str_mv | AT pondrellifederica naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT mucciolilorenzo naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT licchettalaura naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT mostaccibarbara naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT zenesinicorrado naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT tinuperpaolo naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT vignatelliluca naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis AT bisullifrancesca naturalhistoryoflaforadiseaseaprognosticsystematicreviewandindividualparticipantdatametaanalysis |